⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12882833 | 1.00 | CXCR4 (0.41) | — | |
| SCHEMBL12100700 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1870653 | 0.97 | — | — | |
| SCHEMBL15355221 | 0.97 | CXCR4 (0.47) | — | |
| SCHEMBL624731 | 0.93 | — | — | |
| SCHEMBL869844 | 0.90 | — | — | |
| SCHEMBL17119216 | 0.90 | CXCR4 (0.47) | — | |
| SCHEMBL29016828 | 0.90 | ALDH1A1 (0.53) | — | |
| Thiomorpholine SCHEMBL6624599 | 0.90 | ALDH1A1 (0.53) | — | |
| Hydrochloric Acid SCHEMBL18396734 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | claimed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | claimed |
| US-12221431-B2 | Heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-02-11 | — | — | US | claimed |
| EP-4426695-A1 | KRAS G12C INHIBITORS | Frontier Medicines Corporation (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2024-09-05 | — | — | US | claimed |
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKSCI INC. (CA) | 2024-05-21 | — | — | US | claimed |
| US-20240150312-A1 | PYRAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | claimed |
| CN-116444408-B | Multi-target-point disulfiram derivative, pharmaceutical composition and antitumor application thereof | 山东大学 | 2023-09-26 | — | — | CN | claimed |
| CN-116444408-A | Multi-target-point disulfiram derivative, pharmaceutical composition and antitumor application thereof | 山东大学 | 2023-07-18 | — | — | CN | claimed |
| EP-3252042-A1 | BIPYRIDINE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | Sumitomo Chemical Company, Limited (JP) | 2017-12-06 | — | — | EP | claimed |
| EP-3252041-A1 | BIPYRIDINE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | Sumitomo Chemical Company, Limited (JP) | 2017-12-06 | — | — | EP | claimed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | claimed |
| EP-2838534-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | The Board of Trustees of The Leland Stanford Junior University (US) | 2015-02-25 | — | — | EP | claimed |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-23 | — | — | US | claimed |
| WO-2013155338-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-10-17 | — | — | WO | claimed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | claimed |
| US-8022208-B2 | Benzene derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-20 | — | — | US | claimed |
| US-20090054352-A1 | BENZENE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | claimed |
| EP-1947086-A1 | BENZENE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-07-23 | — | — | EP | claimed |